Galectin Therapeutics’ drug candidates in development are new chemical entities generated from naturally occurring carbohydrate polymers using proprietary chemistry.
Galectin has strong intellectual property protection for its belapectin galectin-3 inhibitor (GR-MD-02) extending through at least 2035. The strong patent protection includes composition of matter, various methods of use, and methods of production.